Loading clinical trials...

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133•UCB Biopharma SRL

View on ClinicalTrials.gov

Summary

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must be at least 18 years of age
•Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit
•Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale
•Subject is a candidate for systemic PSO therapy and/or phototherapy
•Female subject of child bearing potential must be willing to use highly effective method of contraception

Exclusion Criteria

•Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic or recurrent chronic infections
•Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection
•Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
•Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
•Presence of active suicidal ideation or positive suicide behavior
•Presence of moderately severe major depression or severe major depression
•Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Locations (105)

Ps0009 946

Phoenix, Arizona, United States

Ps0009 910

Bakersfield, California, United States

Ps0009 919

San Diego, California, United States

Ps0009 906

Boca Raton, Florida, United States

Ps0009 909

Boynton Beach, Florida, United States

Ps0009 912

Coral Gables, Florida, United States

Ps0009 907

Miami, Florida, United States

Ps0009 903

Ocala, Florida, United States

Ps0009 921

Ormond Beach, Florida, United States

Ps0009 918

Tampa, Florida, United States

Key Dates

Start Date

December 6, 2017

Primary Completion Date

January 8, 2019

Completion Date

December 13, 2019

Last Updated

January 28, 2026

Enrollment

567

ACTUAL participants

Conditions

Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisPsoriatic Arthritis

Interventions

Bimekizumab

DRUG

Ustekinumab

DRUG

Placebo

OTHER

A Study of Picankibart in Patients With Active Psoriatic Arthritis

NCT07295509

Psoriatic Arthritis

View study

RECRUITINGPHASE3

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744

Juvenile Psoriatic Arthritis

View study

RECRUITING

Rheumatology Patient Registry and Biorepository

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Picankibart in Patients With Active Psoriatic Arthritis

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Rheumatology Patient Registry and Biorepository

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis